SCHEMBL1780192

SCHEMBL1780192

O=c1oc(-c2ccc([N+](=O)[O-])cc2)ns1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 9/20 0.68
NOTUM Q6P988 1/20 0.54
MAPT P10636 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MMP2 P08253 3/20 0.48
MMP9 P14780 3/20 0.48
MMP8 P22894 3/20 0.48
MMP13 P45452 3/20 0.48
ALDH1A1 P00352 1/20 0.48
GSK3B P49841 2/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
APP P05067 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781484 0.81 PSMB8 (1.00) PSMB8MAPTMEN1KMT2AALDH1A1
SCHEMBL14755644 0.75 PSMB8 (1.00) PSMB8NOTUMMAPTALDH1A1RAB9A
SCHEMBL459541 0.75 PSMB8 (0.68) PSMB8NOTUMRAB9ANPC1
SCHEMBL12614772 0.75 PSMB8 (0.68) PSMB8NOTUMMAPTALDH1A1RAB9A
SCHEMBL18614390 0.75 PSMB8 (0.68) PSMB8MEN1KMT2AALDH1A1RAB9A
SCHEMBL16363828 0.75 PSMB8 (0.68) PSMB8MAPTALDH1A1
SCHEMBL1781945 0.75 PSMB8 (0.68) PSMB8NOTUMMAPTALDH1A1RAB9A
SCHEMBL9627131 0.75 PSMB8 (0.68) PSMB8
SCHEMBL9720227 0.74 MAPT (0.70) NOTUMMAPTMEN1KMT2AMMP2
SCHEMBL14755476 0.73 PSMB8 (0.60) PSMB8MAPTALDH1A1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118274-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER CORNELL RESEARCH FOUNDATION, INC. (US) 2011-05-19 US claimed
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof BRIDGENE BIOSCIENCES, INC. (US) 2026-03-24 US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 US disclosed
CN-116490201-A Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use 布里奇恩生物科学公司 2023-07-25 CN disclosed
EP-4175658-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF Bridgene Biosciences, Inc. (US) 2023-05-10 EP disclosed
WO-2022006548-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. (US) 2022-01-06 WO disclosed
US-20110118274-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER CORNELL RESEARCH FOUNDATION, INC. (US) 2011-05-19 US disclosed
WO-2009026579-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER CORNELL RESEARCH FOUNDATION, INC. (US) 2009-02-26 WO disclosed
US-7465748-B2 Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
US-20060229295-A1 Amide derivatives ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) 2006-10-12 US disclosed
EP-1652843-A1 AMIDE DERIVATIVES Astellas Pharma Inc. (JP) 2006-05-03 EP disclosed
US-4261728-A PREEMERGENT ACTIVITY MONSANTO COMPANY (US) 1981-04-14 US disclosed
US-4187099-A 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides MONSANTO COMPANY (US) 1980-02-05 US disclosed
US-4144047-A SOYBEANS MONSANTO COMPANY (US) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof YAP1, TEAD1, TEAD2 PSMB8 2424/4885NOTUM 4322/4885MAPT 371/4885
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF TEAD1, TEAD2, TEAD3 PSMB8 2694/4885NOTUM 3761/4885MAPT 433/4885
US-20110118274-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER PSMB1, PSME1, PSMB2 PSMB8 22/4885NOTUM 3210/4885MAPT 2481/4885
US-20060229295-A1 Amide derivatives VAC14, HDAC8, ZC3HAV1 PSMB8 2376/4885NOTUM 2951/4885MAPT 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.